Mangoceuticals (MGRX) Cash from Financing Activities (2023 - 2025)

Mangoceuticals has disclosed Cash from Financing Activities across 3 years of filings, most recently posting $2.1 million for Q4 2025.

• In Q4 2025, Cash from Financing Activities rose 85.61% year-over-year to $2.1 million; the TTM figure through Dec 2025 stood at $7.3 million (up 76.12% YoY), while the FY2025 annual figure was $7.3 million, up 76.12% from the prior year.
• Cash from Financing Activities came in at $2.1 million for Q4 2025 at Mangoceuticals, up from $1.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $5.0 million in Q1 2023 to a low of $267500.0 in Q1 2024.
• Average Cash from Financing Activities over 3 years is $1.7 million, with a median of $1.3 million recorded in 2025.
• Year-over-year, Cash from Financing Activities plunged 94.65% in 2024 and soared 754.21% in 2025.
• Over 3 years, Cash from Financing Activities stood at $1.2 million in 2023, then fell by 6.46% to $1.1 million in 2024, then surged by 85.61% to $2.1 million in 2025.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $2.1 million in Q4 2025, $1.6 million in Q3 2025, and $1.3 million in Q2 2025.